In the BioHarmony Drug Report Database

"Preview" Icon

Peginterferon alfa-2a

Pegasys (peginterferon alfa-2a) is a protein pharmaceutical. Peginterferon alfa-2a was first approved as Pegasys on 2002-06-20. It is used to treat brain neoplasms, chronic hepatitis b, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA. It has been approved in Europe to treat chronic hepatitis b and chronic hepatitis c.

 

Trade Name

 

Pegasys
 

Common Name

 

peginterferon alfa-2a
 

ChEMBL ID

 

CHEMBL1201560
 

Indication

 

brain neoplasms, chronic hepatitis b, chronic hepatitis c, colorectal neoplasms, cryoglobulinemia, essential thrombocythemia, hairy cell leukemia, hemangioma, hepatitis d, hepatocellular carcinoma, hypereosinophilic syndrome, ileal neoplasms, kaposi sarcoma, macular degeneration, melanoma, multiple myeloma, mycosis fungoides, renal cell carcinoma, sezary syndrome, skin neoplasms, skin ulcer, thrombocytopenia, warts
 

Drug Class

 

Pegylated compounds

Image (chem structure or protein)

Peginterferon alfa-2a structure rendering